Our Pipeline

Currently, four Inhibrx programs are in ongoing clinical trials: three for the treatment of various cancers, and one for Alpha-1 Antitrypsin Deficiency (AATD).

The Candidates

Phase 1
Phase 2
Phase 3


Our Recombinant Alpha-1 Anti- trypsin Fc-Fusion Protein (AAT-Fc)

Orphan / Respiratory

INBRX-101 is a recombinant human AAT-Fc fusion protein therapeutic candidate currently being evaluated for the treatment of AATD. Early clinical data has demonstrated a promising pharmacokinetic profile that we believe supports a dosing schedule of every three to four weeks to achieve continuous normal AAT serum concentrations, a significant improvement from patients’ current regimen.

Learn more Phase 1 Trial
Inbrx 101


Our Tetravalent DR5 Agonist


INBRX-109 is a precisely engineered tetravalent sdAb-based therapeutic candidate that agonizes DR5 to induce tumor selective programmed cell death.

Learn more Phase 1 Trial
Inbrx 109


Our Hexavalent OX40 Agonist


INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40 currently being evaluated in patients with locally advanced or metastatic solid tumors. Signaling through OX40 provides co-stimulation that promotes T-cell expansion, enhanced effector function and memory cell formation, and prevents activation-induced cell death.

Learn more clinicaltrials.gov
Inbrx 106